Medtronic (Booth 826) is featuring clinical research updates from its international RESOLUTE trials, designed to assess the safety and efficacy of its Endeavor Resolute drug-eluting stent (DES) system, which is an investigational device in the U.S., but commercially available in Europe.

Clinical research teams led by interventional cardiologists James Carr, MD, at East Texas Medical Center in the United States and Prof. Dr. Franz-Josef Neumann at the Heart Center of Bad Krozingen in Germany are enrolling patients in RESOLUTE US (R-US) and RESOLUTE International (R-Int), respectively. 

The Endeavor Resolute DES uses the proprietary BioLinx polymer, which was designed to meet the same biocompatibility requirements as the phosphorylcholine (PC) polymer used in Medtronic's Endeavor stent. Compared to the PC polymer, the BioLinx polymer is designed to extend the duration of drug exposure in the vessel.